Boaz Hirshberg

Boaz Hirshberg, MD, MBA, joined Regeneron in 2021 and serves as Senior Vice President, Clinical Sciences General Medicine, leading strategic program direction and late stage clinical development for a broad range of therapeutic areas including ophthalmology, cardiovascular and metabolic, pain and neurology, and infectious and rare diseases. Before joining Regeneron, Dr. Hirshberg was Executive Vice President, Chief Medical Officer and Head of Global Development at BOL Pharma, a biotech developing medical cannabis therapeutics, where he directed preclinical and clinical development, regulatory, pharmacovigilance and medical affairs. Prior to BOL, he spent 12 years at AstraZeneca/MedImmune in roles of increasing responsibility, ultimately building and overseeing the Cardiovascular Renal and Metabolism clinical therapeutic area at MedImmune. Dr. Hirshberg completed his undergraduate and Medical Degrees at the Hebrew University and is Board Certified in internal medicine, following his residency at the Hadassah Medical center in Jerusalem. He received his MBA in Health Care Administration from Wilmington University.